Bernabé, Reyes http://orcid.org/0000-0003-0312-9195
Liu, Stephen V.
Sánchez-Gastaldo, Amparo
Alonso García, Miriam
Article History
Received: 18 April 2023
Accepted: 7 December 2023
First Online: 27 January 2024
Declarations
:
: Stephen V. Liu has been on an advisory board for or acted as a consultant for AbbVie, Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck/MSD, Merus, Novartis, Regeneron, Sanofi, Takeda and Turning Point Therapeutics and has received research funding (to institution) from Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Nuvalent, RAPT and Turning Point Therapeutics. Reyes Bernabé, Amparo Sánchez-Gastaldo and Miriam Alonso García declare that they have no competing interests.
: IMpower133 was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee at each site. All patients provided written informed consent. The patient presented in this case report provided written informed consent to participate in the IMpower133 study. Consent for publication of their anonymized details was obtained on 23 June 2022.